Interaction of p53 with the CCT Complex Promotes Protein Folding and Wild-Type p53 Activity

Molecular Cell

Volumn 50, Issue 6, 2013, Pages 805-817

  Trinidad, Antonio Garcia ^a   Muller, Patricia A J ^a   Cuellar, Jorge ^b   Klejnot, Marta ^a   Nobis, Max ^a   Valpuesta, José María ^b   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN; MUTANT PROTEIN; PROTEIN CCT; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CELL GROWTH; CELL INVASION; CELL MOTILITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; GENE EXPRESSION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN SUBUNIT; TRANSCRIPTION REGULATION; WILD TYPE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENES, REPORTER; GROUP II CHAPERONINS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LUCIFERASES, FIREFLY; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; PROTEIN STRUCTURE, QUATERNARY; PROTEIN SUBUNITS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880831748     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.05.002     Document Type: Article

References (53)

1. Abe Y., Yoon S.O., Kubota K., Mendoza M.C., Gygi S.P., Blenis J. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J.Biol. Chem. 2009, 284:14939-14948.
2. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
3. Andrews P., He Y.J., Xiong Y. Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function. Oncogene 2006, 25:4534-4548.
4. Ano Bom A.P., Rangel L.P., Costa D.C., de Oliveira G.A., Sanches D., Braga C.A., Gava L.M., Ramos C.H., Cepeda A.O., Stumbo A.C., et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J.Biol. Chem. 2012, 287:28152-28162.
5. Beckerman R., Prives C. Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2010, 2:a000935.
6. Blagosklonny M.V., Toretsky J., Bohen S., Neckers L. Mutant conformation of p53 translated invitro or invivo requires functional HSP90. Proc. Natl. Acad. Sci. USA 1996, 93:8379-8383.
7. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., Lane D.P., Fersht A.R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 1997, 94:14338-14342.
8. Bullock A.N., Henckel J., Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000, 19:1245-1256.
9. Candau R., Scolnick D.M., Darpino P., Ying C.Y., Halazonetis T.D., Berger S.L. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 1997, 15:807-816.
10. Coffill C.R., Muller P.A., Oh H.K., Neo S.P., Hogue K.A., Cheok C.F., Vousden K.H., Lane D.P., Blackstock W.P., Gunaratne J. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep. 2012, 13:638-644.
11. Collavin L., Lunardi A., Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010, 17:901-911.
12. Douglas N.R., Reissmann S., Zhang J., Chen B., Jakana J., Kumar R., Chiu W., Frydman J. Dual action of ATP hydrolysis couples lid closure to substrate release into the group II chaperonin chamber. Cell 2011, 144:240-252.
13. Feldman D.E., Spiess C., Howard D.E., Frydman J. Tumorigenic mutations in VHL disrupt folding invivo by interfering with chaperonin binding. Mol. Cell 2003, 12:1213-1224.
14. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012, 26:1268-1286.
15. Friedlander P., Legros Y., Soussi T., Prives C. Regulation of mutant p53 temperature-sensitive DNA binding. J.Biol. Chem. 1996, 271:25468-25478.
16. Frydman J., Nimmesgern E., Ohtsuka K., Hartl F.U. Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature 1994, 370:111-117.
17. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990, 9:1595-1602.
18. Gómez-Puertas P., Martín-Benito J., Carrascosa J.L., Willison K.R., Valpuesta J.M. The substrate recognition mechanisms in chaperonins. J.Mol. Recognit. 2004, 17:85-94.
19. Grantham J., Brackley K.I., Willison K.R. Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp. Cell Res. 2006, 312:2309-2324.
20. Hartl F.U., Bracher A., Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 2011, 475:324-332.
21. Hayer-Hartl M.K., Ewbank J.J., Creighton T.E., Hartl F.U. Conformational specificity of the chaperonin GroEL for the compact folding intermediates of alpha-lactalbumin. EMBO J. 1994, 13:3192-3202.
22. Hollstein M., Hainaut P. Massively regulated genes: the example of TP53. J.Pathol. 2010, 220:164-173.
23. Joerger A.C., Fersht A.R. Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv. Cancer Res. 2007, 97:1-23.
24. Joly E.C., Tremblay E., Tanguay R.M., Wu Y., Bibor-Hardy V. TRiC-P5, a novel TCP1-related protein, is localized in the cytoplasm and in the nuclear matrix. J.Cell Sci. 1994, 107:2851-2859.
25. Kitamura A., Kubota H., Pack C.G., Matsumoto G., Hirayama S., Takahashi Y., Kimura H., Kinjo M., Morimoto R.I., Nagata K. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat. Cell Biol. 2006, 8:1163-1170.
26. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
27. Lee C.W., Arai M., Martinez-Yamout M.A., Dyson H.J., Wright P.E. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry 2009, 48:2115-2124.
28. Liu X., Lin C.Y., Lei M., Yan S., Zhou T., Erikson R.L. CCT chaperonin complex is required for the biogenesis of functional Plk1. Mol. Cell. Biol. 2005, 25:4993-5010.
29. Liu B., Larsson L., Caballero A., Hao X., Oling D., Grantham J., Nyström T. The polarisome is required for segregation and retrograde transport of protein aggregates. Cell 2010, 140:257-267.
30. Matus D.Q., Li X.Y., Durbin S., Agarwal D., Chi Q., Weiss S.J., Sherwood D.R. Invivo identification of regulators of cell invasion across basement membranes. Sci. Signal. 2010, 3:ra35.
31. Mayer M.P. Gymnastics of molecular chaperones. Mol. Cell 2010, 39:321-331.
32. Mayer S., Rüdiger S., Ang H.C., Joerger A.C., Fersht A.R. Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability invitro. J.Mol. Biol. 2007, 372:268-276.
33. Meek D.W., Anderson C.W. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb. Perspect. Biol. 2009, 1:a000950.
34. Melville M.W., McClellan A.J., Meyer A.S., Darveau A., Frydman J. The Hsp70 and TRiC/CCT chaperone systems cooperate invivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol. Cell. Biol. 2003, 23:3141-3151.
35. Meyer A.S., Gillespie J.R., Walther D., Millet I.S., Doniach S., Frydman J. Closing the folding chamber of the eukaryotic chaperonin requires the transition state of ATP hydrolysis. Cell 2003, 113:369-381.
36. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990, 62:671-680.
37. Milner J., Cook A., Sheldon M. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene 1987, 1:453-455.
38. Muller P.A., Caswell P.T., Doyle B., Iwanicki M.P., Tan E.H., Karim S., Lukashchuk N., Gillespie D.A., Ludwig R.L., Gosselin P., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139:1327-1341.
39. Muller P.A., Vousden K.H., Norman J.C. p53 and its mutants in tumor cell migration and invasion. J.Cell Biol. 2011, 192:209-218.
40. Muller P.A., Trinidad A.G., Timpson P., Morton J.P., Zanivan S., van den Berghe P.V., Nixon C., Karim S.A., Caswell P.T., Noll J.E., et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2013, 32:1252-1265.
41. Nikolaev A.Y., Li M., Puskas N., Qin J., Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003, 112:29-40.
42. Siegers K., Waldmann T., Leroux M.R., Grein K., Shevchenko A., Schiebel E., Hartl F.U. Compartmentation of protein folding invivo: sequestration of non-native polypeptide by the chaperonin-GimC system. EMBO J. 1999, 18:75-84.
43. Tam S., Geller R., Spiess C., Frydman J. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat. Cell Biol. 2006, 8:1155-1162.
44. Thulasiraman V., Yang C.F., Frydman J. Invivo newly translated polypeptides are sequestered in a protected folding environment. EMBO J. 1999, 18:85-95.
45. Valpuesta J.M., Martín-Benito J., Gómez-Puertas P., Carrascosa J.L., Willison K.R. Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT. FEBS Lett. 2002, 529:11-16.
46. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
47. Walerych D., Olszewski M.B., Gutkowska M., Helwak A., Zylicz M., Zylicz A. Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. Oncogene 2009, 28:4284-4294.
48. Wilcken R., Wang G., Boeckler F.M., Fersht A.R. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc. Natl. Acad. Sci. USA 2012, 109:13584-13589.
49. Willison K., Lewis V., Zuckerman K.S., Cordell J., Dean C., Miller K., Lyon M.F., Marsh M. The t complex polypeptide 1 (TCP-1) is associated with the cytoplasmic aspect of Golgi membranes. Cell 1989, 57:621-632.
50. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., Rudyak S., Cornelis A., Rozenski J., Zwolinska A., Marine J.C., et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 2011, 7:285-295.
51. Yam A.Y., Xia Y., Lin H.T., Burlingame A., Gerstein M., Frydman J. Defining the TRiC/CCT interactome links chaperonin function to stabilization of newly made proteins with complex topologies. Nat. Struct. Mol. Biol. 2008, 15:1255-1262.
52. Yébenes H., Mesa P., Muñoz I.G., Montoya G., Valpuesta J.M. Chaperonins: two rings for folding. Trends Biochem. Sci. 2011, 36:424-432.
53. Zhang W., Guo X.Y., Hu G.Y., Liu W.B., Shay J.W., Deisseroth A.B. A temperature-sensitive mutant of human p53. EMBO J. 1994, 13:2535-2544.